Literature DB >> 19672902

The road not taken: a path to curing type 1 diabetes?

Michael J Haller1, Mark A Atkinson, Desmond A Schatz.   

Abstract

The past quarter century has seen a rapid increase in our knowledge about the natural history of autoimmune type 1 diabetes. However, we stand unable to achieve our ultimate goal of preventing or reversing this disease. This viewpoint discusses controversies in current management of type 1 diabetes, the challenges in translating promising studies from mouse models of the disease to humans, hurdles faced in designing optimal prevention and intervention studies, and potential strategies to overcome these obstacles.

Entities:  

Mesh：

Year:  2009        PMID： 19672902      PMCID： PMC4085751          DOI： 10.1002/eji.200939517

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


  26 in total

1.  Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes.

Authors:  Marceline Huppmann; Andrea Baumgarten; Anette-G Ziegler; Ezio Bonifacio
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

Review 2.  Type 1 diabetes mellitus: etiology, presentation, and management.

Authors:  Michael J Haller; Mark A Atkinson; Desmond Schatz
Journal:  Pediatr Clin North Am       Date:  2005-12       Impact factor: 3.278

3.  Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group.

Authors: 
Journal:  Diabetes       Date:  1988-11       Impact factor: 9.461

4.  Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.

Authors:  I Raz; D Elias; A Avron; M Tamir; M Metzger; I R Cohen
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

5.  Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus.

Authors:  J Silverstein; N Maclaren; W Riley; R Spillar; D Radjenovic; S Johnson
Journal:  N Engl J Med       Date:  1988-09-08       Impact factor: 91.245

6.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Authors:  Bart Keymeulen; Evy Vandemeulebroucke; Anette G Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandene; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

7.  Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group.

Authors: 
Journal:  Diabetologia       Date:  1999-01       Impact factor: 10.122

8.  Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group.

Authors: 
Journal:  J Pediatr       Date:  1994-08       Impact factor: 4.406

9.  Linear loss of insulin secretory capacity during the last six months preceding IDDM. No effect of antiedematous therapy with ketotifen.

Authors:  K P Böhmer; H Kolb; B Kuglin; J Zielasek; A Hübinger; E F Lampeter; B Weber; V Kolb-Bachofen; H U Jastram; J Bertrams
Journal:  Diabetes Care       Date:  1994-02       Impact factor: 19.112

10.  European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.

Authors:  E A M Gale; P J Bingley; C L Emmett; T Collier
Journal:  Lancet       Date:  2004-03-20       Impact factor: 79.321
View more
  3 in total

Review 1.  Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.

Authors:  Frank Waldron-Lynch; Kevan C Herold
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

2.  Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development.

Authors:  Zuoxiang Xiao; Abdiaziz S Mohamood; Sophia Uddin; Rachel Gutfreund; Chiaki Nakata; Andrew Marshall; Hiroaki Kimura; Patrizio Caturegli; Karl L Womer; Yanfei Huang; Chunfa Jie; Shukti Chakravarti; Jonathan P Schneck; Hideo Yagita; Abdel Rahim A Hamad
Journal:  Am J Pathol       Date:  2011-06-15       Impact factor: 4.307

3.  Induction of mixed chimerism with MHC-mismatched but not matched bone marrow transplants results in thymic deletion of host-type autoreactive T-cells in NOD mice.

Authors:  Jeremy Racine; Miao Wang; Chunyan Zhang; Chia-Lei Lin; Hongjun Liu; Ivan Todorov; Mark Atkinson; Defu Zeng
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.